Ustekinumab Biosimilar, Human IL-12 / IL-23 Monoclonal Antibody

Ustekinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Ustekinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. Ustekinumab biosimilar uses the same protein sequences as the therapeutic antibody ustekinumab.

Product Details
Species Reactivity	Human
Source	Mammalian cells
Host/Isotype	Human IgG1 lambda
Class	Monoclonal
Type	Antibody
Immunogen	The human interleukin-12 (IL-12) and interleukin-23 (IL-23)
Clone	Ustekinumab Biosimilar
Conjugate	Unconjugated
Purity	>95%
Molecular Weight	145.63 kDa
Protein Concentration	1 mg/ml
Formulation	Liquid
Storage Condition	4°C for short time, -20°C or -80°C for long time.
Storage Buffer	0.2 uM filtered PBS solution, pH 7.4